15.17
전일 마감가:
$15.58
열려 있는:
$15.55
하루 거래량:
509.55K
Relative Volume:
0.49
시가총액:
$925.13M
수익:
$13.73M
순이익/손실:
$-114.48M
주가수익비율:
-8.2365
EPS:
-1.8418
순현금흐름:
$-78.49M
1주 성능:
-1.04%
1개월 성능:
-1.24%
6개월 성능:
+10.65%
1년 성능:
-36.83%
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
JANX
Janux Therapeutics Inc
|
15.17 | 949.53M | 13.73M | -114.48M | -78.49M | -1.8418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Overweight → Underweight |
| 2026-04-15 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-10 | 개시 | Stifel | Buy |
| 2025-09-10 | 개시 | Truist | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics Inc (JANX) Balance Sheet - TradingKey
JANX|Janux Therapeutics Inc|Price:15.680|Chg%:+0.350 - TradingKey
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
JANX|Janux Therapeutics Inc|Price:15.510|Chg%:+0.180 - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
JANX|Janux Therapeutics Inc|Price:15.635|Chg%:+0.305 - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics Inc (JANX) Income Statement - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance Canada
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership - Moomoo
Janux Therapeutics Inc (JANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Janux Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Barrett Ronald W - Moomoo
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Powerhouse with 131.70% Potential Upside - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (JANX) Movement - Stock Traders Daily
Janux Therapeutics (JANX) Gains Momentum: Biotech Stock Rises 2.65% as Buyers Test Key ResistanceIPO Entry Watch - dars.gov.et
Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? - MSN
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics (NASDAQ: JANX) CEO exercises 7,000 options at $4.21, boosts holdings - Stock Titan
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story? - Yahoo Finance
Janux Therapeutics (JANX) Is Up 13.6% After Removal From Multiple Russell Growth IndexesWhat's Changed - simplywall.st
Janux Therapeutics Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises 6%Dividend Cut Risk - dars.gov.et
Price to earnings forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Discipline and Rules-Based Execution in JANX Response - Stock Traders Daily
Janux Therapeutics (JANX) Gains 2.47% as Shares Hold Above Key Support LevelDiagonal Spread Trade - dars.gov.et
JANX Forecast — Price Target — Prediction for 2027 - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX) - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (BX:JANX) - TradingView
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Janux Therapeutics Inc (JANX) - The Globe and Mail
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia
Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Janux Therapeutics announces departure of chief medical officer - Investing.com
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Janux Therapeutics Inc 주식 (JANX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr |
Jun 02 '26 |
Sale |
14.03 |
4,059 |
56,944 |
75,941 |
자본화:
|
볼륨(24시간):